This Medical News article is an interview with retired neurologist Daniel Gibbs, who is living with Alzheimer disease.
Risultati per: Sildenafil come potenziale trattamento per il morbo di Alzheimer
Questo è quello che abbiamo trovato per te
Linee guida sul trattamento delle infezioni da batteri Gram-negativi.
Terapia derivata dalle cellule staminali contro il cancro al fegato resistente al trattamento
Scoperto bersaglio per il trattamento del cancro al pancreas
Nuovi criteri diagnostici per la malattia di Alzheimer
Linea guida sull’incontinenza dopo il trattamento della prostata
Study: 2 APOE4 Copies May Indicate Genetic Form of Alzheimer Disease
Almost all people who inherited 2 identical copies of the APOE4 gene variant had abnormally high levels of amyloid in their cerebrospinal fluid and brain by age 65 years, according to a new study that combined data from more than 3200 brain donors and about 10 000 participants with clinical data.
Alzheimer’s Disease, Biomarkers, and mAbs — What Does Primary Care Need?
New England Journal of Medicine, Ahead of Print.
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease
New England Journal of Medicine, Volume 390, Issue 23, Page 2156-2164, June 20, 2024.
Protection against Alzheimer’s Disease with APOE Christchurch Variant — How?
New England Journal of Medicine, Volume 390, Issue 23, Page 2212-2213, June 20, 2024.
Homozygosity for R47H in TREM2 and the Risk of Alzheimer’s Disease
New England Journal of Medicine, Volume 390, Issue 23, Page 2217-2219, June 20, 2024.
Risks of Harm in Alzheimer Disease by Amyloid Lowering
This Viewpoint discusses how data gaps in published research impede clinicians’ ability to clearly discuss the risks and benefits of amyloid-lowering drugs for treating Alzheimer disease.
Il controllo del mercato dei farmaci per l’Alzheimer
I consulenti dell’Fda hanno approvato il farmaco di Eli Lilly. Entro la fine dell’anno si attende l’ok definitivo da parte dell’Ente regolatorio
Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension
Circulation, Ahead of Print. BACKGROUND:Sildenafil, approved for pulmonary arterial hypertension (PAH), has a recommended adult dose of 20 mg TID, with a previously approved 5-mg TID dose by the US Food and Drug Administration. Safety concerns arose because of common off-label use of higher doses, particularly after pediatric data linked higher doses to increased mortality. To assess this, the Food and Drug Administration mandated a study evaluating the effects of various sildenafil doses on mortality in adults with PAH.METHODS:This randomized, double-blind study compared sildenafil at doses of 5, 20, or 80 mg TID in adults with PAH. The primary objective was noninferiority of 80 mg of sildenafil versus 5 mg for all-cause mortality. Secondary end points included time to clinical worsening and change in 6-minute walk distance at 6 months. Interim analyses were planned at 50% and 75% of the anticipated mortality events. Safety and tolerability were assessed in the intention-to-treat population.RESULTS:The study was halted after the first interim analysis, demonstrating noninferiority for 80 mg of sildenafil versus 5 mg. Of 385 patients enrolled across all dose groups, 78 died. The primary analysis showed a hazard ratio of 0.51 (99.7% CI, 0.22–1.21;P
Identificata una nuova forma genetica della malattia di Alzheimer
Alzheimer, il 15% delle forme è di origine genetica
Su Nature uno studio spagnolo suggerisce che quasi tutti coloro che hanno due copie della variante genetica ApoE4 sviluppano la malattia